Bluejay Diagnostics announced a private placement to raise up to $23.6 million, including $8.5 million upfront, to extend its cash runway into early 2027. The funds will support FDA submission and commercialization of its rapid sepsis testing system, Symphony. The company also formed a strategic partnership with Argonaut Manufacturing Services to develop scalable U.S.-based manufacturing and strengthen its commercial infrastructure. This move aims to enhance product distribution, supply chain resilience, and reduce risks from international sourcing and tariffs, positioning Bluejay for growth in the medical diagnostics market.
Valneva declared its shares and voting rights status as of May 31, 2026, reporting 189,771,237 ordinary shares and a total of 204,238,965 exercisable voting rights after accounting for double voting rights on some shares. This update is important for...
Integrated Quantum Technologies introduced VEIL™, a privacy-focused tool integrated into Snowflake's AI Data Cloud, which removes personally identifiable information (PII) from data before it is used in AI and machine learning models. This approach a...
Ed Yardeni, president of Yardeni Research, forecasts the Federal Reserve will raise interest rates at its July 29 meeting, a view that contrasts with the market's low expectations for a rate hike this summer. Yardeni cites a resilient economy, strong...
Veeva Systems is preparing to report Q1 earnings on June 3, 2026, with revenue guidance between $855M and $858M and an EPS estimate of $2.13, reflecting year-over-year growth. The company is transitioning from Salesforce to its own Vault CRM platform...
Nordea Bank Abp announced an increase in the base rate margin for all Bear Certificates and Mini Future Shorts linked to Sivers Semiconductors AB. This change is due to poor liquidity and higher lending costs in the underlying asset. The margin incre...
